NCT04389307

Brief Summary

Overactive bladder (OAB) is a symptom complex defined as urgency, with or without urge urinary incontinence (UUI), usually with frequency and nocturia, in the absence of urinary tract infection. Currently, a wide range of therapeutic options exist for the treatment of OAB. These include first-line conservative (physical) therapies which focus on electrical stimulation (ES) and behavioral therapies such as lifestyle modifications, bladder training (BT), pelvic floor muscle training with or without biofeedback, second-line therapies which are pharmacologic, and third-line therapies which either neuromodulate or chemodenervate the bladder. In clinical practice, BT and Intravaginal ES (IVES) are frequently used together in the treatment of women with OAB, but the evidences/results of the combined (BT+IVES) use of these two treatment options are so rare that they can be neglected in the literature. There is only one study including BT+ES treatment arm (one of the four treatment arms) in women with idiopathic OAB in the literature. In a study, BT+ES was not found to be effective both from BT alone and from the untreated control group. While interpreting the results of this study, it should be take into consideration that patients treated received relatively few treatment sessions (nine treatment sessions, once weekly) in this study. In addition, in the light of authors clinical experience, the investigators think that this issue is still open for research. Moreover, there is no recommendation on conservative combinations in the guidelines due to insufficient data. This study is the first prospective randomized controlled trial that compares the efficacy of BT and BT plus IVES in women with idiopathic OAB. In this study, the investigators aimed to evaluate the efficacy of BT with and without IVES on incontinence-related QoL and clinical parameters in women with idiopathic OAB.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 12, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 15, 2020

Completed
17 days until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
Last Updated

May 25, 2021

Status Verified

May 1, 2021

Enrollment Period

6 months

First QC Date

May 12, 2020

Last Update Submit

May 24, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • incontinence episodes-incontinence related outcomes measures

    Patients with a 50% or greater reduction in incontinence episodes were consider positive responders (number of voiding per day)

    8 weeks

Secondary Outcomes (3)

  • frequency of voiding-incontinence related outcomes measures

    8 weeks

  • nocturia frequency- incontinence related outcomes measures

    8 weeks

  • incontinence related quality of life questionnaire

    8 weeks

Study Arms (2)

Group 1: Bladder Training - Control group

OTHER

Specific goals are to correct faulty habit patterns of frequent urination, improve control over bladder urgency, prolong voiding intervals, increase bladder capacity, reduce incontinence episodes and restore patient confidence in controlling bladder function

Other: Bladder Training

Group 2: Bladder Training+Intra Vaginal Electrical Stimulation

ACTIVE COMPARATOR

IVES was performed in lithotomy position via Enraf Nonius Myomed 632 device with a vaginal probe. IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24-session treatment program of ES. The stimulation parameters were frequency at 10 Hz, a 5-10s work-rest cycle and 100 ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 0-100 mA. The intensity was controlled according to patients' discomfort level feedback

Other: Electrical stimulation (IVES)Other: Bladder Training

Interventions

IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.

Group 2: Bladder Training+Intra Vaginal Electrical Stimulation

Bladder Training

Group 1: Bladder Training - Control groupGroup 2: Bladder Training+Intra Vaginal Electrical Stimulation

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women over the age of 18 with clinical diagnosis of idiopathic OAB
  • Urodynamically diagnosed detrusor overactivity
  • The strength of pelvic floor muscle 3/5 and more
  • Able to give written, informed consent
  • Able to understand the procedures, advantages and possible side effects
  • Willing and able to complete the voiding diary and QoL questionnaire

You may not qualify if:

  • History of conservative therapy (BT, ES) for OAB within 3 months
  • Previously treated with antimuscarinics (within 4 weeks)
  • Pregnancy or intention to become pregnant during the study
  • Current vulvovaginitis or urinary tract infections or malignancy
  • History of urogynecological surgery within 3 months
  • Anatomic structural disorders of genital region that could not allow to apply the vaginal probe
  • Having stage 2 or more according to the pelvic organ prolapse quantification
  • Cardiac pacemaker or implanted defibrillator
  • Neurogenic bladder, signs of neurologic abnormalities at objective examination; history of the peripheral or central neurologic pathology
  • Ultrasonographic evidence of residual urine volume more than 100 ml
  • Allergy to condom or lubricant gel that is used with perineometer/vaginal probe

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hakan Alkan

Denizli, None Selected, 20100, Turkey (Türkiye)

Location

MeSH Terms

Interventions

Electric Stimulation

Intervention Hierarchy (Ancestors)

Physical StimulationInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

May 12, 2020

First Posted

May 15, 2020

Study Start

June 1, 2020

Primary Completion

December 1, 2020

Study Completion

December 31, 2020

Last Updated

May 25, 2021

Record last verified: 2021-05

Locations